Evaluation of CYP2C19-Mediated Pharmacokinetic Drug Interaction of Tegoprazan, Compared with Vonoprazan or Esomeprazole

ConclusionTegoprazan, unlike vonoprazan and esomeprazole, exhibited negligible CYP2C19-mediated PK interaction. It suggests that as an alternative to other acid-reducing agents, tegoprazan can be used concomitantly with CYP2C19 substrates in clinical settings.Trial RegistrationClinicaltrials.gov identifier: NCT04568772 (Registered on September 29, 2020).
Source: Clinical Pharmacokinetics - Category: Drugs & Pharmacology Source Type: research